Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand

被引:11
作者
Cavallari, Ilaria [1 ]
Maddaloni, Ernesto [2 ,3 ]
机构
[1] Campus Biomed Univ Rome, Dept Cardiovasc Sci, Rome, Italy
[2] Campus Biomed Univ Rome, Unit Endocrinol & Diabet, Dept Med, Via Alvaro Portillo 200, Rome, Italy
[3] Sapienza Univ Rome, Expt Med, Rome, Italy
关键词
cardiovascular disease; clinical trials; SGLT-2; inhibitors; HEART-FAILURE; EMPAGLIFLOZIN; MORTALITY; RISK;
D O I
10.1002/dmrr.3124
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The recent results of the DECLARE-TIMI 58 trial forces a profound reflection about the cardiovascular protection conferred by SGLT-2 inhibitors. DECLARE-TIMI 58, the largest cardiovascular outcome trial in diabetes, failed to show a significant reduction in the risk of major adverse cardiovascular events (MACEs) conferred by dapagliflozin compared with placebo. However, a lower rate of hospitalization for heart failure was reported. Whilst the lack of benefits on MACE may seem in contrast with the results of previous SGLT-2 inhibitors cardiovascular outcome trials, DECLARE clearly delineates the real cardiovascular effects of SGLT-2 inhibitors, which mainly tackle heart failure. Differences in study design and population enrolled are crucial to correctly value each molecule and to translate results of clinical trials in daily clinical practise.
引用
收藏
页数:3
相关论文
共 12 条
[11]  
Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI [10.1056/NEJMoa1812389, 10.1056/NEJMc1902837]
[12]   Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].
Zinman, Bernard ;
Wanner, Christoph ;
Lachin, John M. ;
Fitchett, David ;
Bluhmki, Erich ;
Hantel, Stefan ;
Mattheus, Michaela ;
Devins, Theresa ;
Johansen, Odd Erik ;
Woerle, Hans J. ;
Broedl, Uli C. ;
Inzucchi, Silvio E. ;
Aizenberg, D. ;
Ulla, M. ;
Waitman, J. ;
De Loredo, L. ;
Farias, J. ;
Fideleff, H. ;
Lagrutta, M. ;
Maldonado, N. ;
Colombo, H. ;
Ferre Pacora, F. ;
Wasserman, A. ;
Maffei, L. ;
Lehman, R. ;
Selvanayagam, J. ;
d'Emden, M. ;
Fasching, P. ;
Paulweber, B. ;
Toplak, H. ;
Luger, A. ;
Drexel, H. ;
Prager, R. ;
Schnack, C. ;
Schernthaner, G. ;
Fliesser-Goerzer, E. ;
Kaser, S. ;
Scheen, A. ;
Van Gaal, L. ;
Hollanders, G. ;
Kockaerts, Y. ;
Capiau, L. ;
Chachati, A. ;
Persu, A. ;
Hermans, M. ;
Vantroyen, D. ;
Vercammen, C. ;
Van de Borne, P. ;
Mathieu, C. ;
Benhalima, K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) :2117-2128